JENNINGS POLICY STRATEGIES for GENERIC PHARMACEUTICAL ASSOCIATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HAYES | HEALTH COUNSEL, US SENATOR EVAN BAYH |
| CHRISTOPHER JENNINGS | — |
Pharmacy PHA
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including -- but not limited to -- H.R. 1038, S. 623, H.R. 5629).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HAYES | HEALTH COUNSEL, US SENATOR EVAN BAYH |
| CHRISTOPHER JENNINGS | — |
Medicare/Medicaid MMM
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace, including Medicaid rebates.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE HAYES | HEALTH COUNSEL, US SENATOR EVAN B AYH |
| CHRISTOPHER JENNINGS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.